Catégorie dans Recherche

In this multi-center study (@ChuSteJustine @HopitalChildren @BCCHF @HopRobertDebre), we found that children living with #crohnsdisease who failed at least 1 antiTNF, had at 12 months,

38.6% clinical remission 

47.8% clinical response

with #ustekinumab

#Jantchoulab

https://tinyurl.com/y7bju3yq

Un sou qui ne vaut pas grand-chose mais qui a coûté à la société beaucoup de dollars.

Parents : soyez vigilants dites à vos enfants que la bouche ce n’est point une tirelire.

Enfants : écouter vos parents… écouter les conseils du docteur J !!! ce n’est pas toujours plaisant de venir à l’hôpital et y passer des heures et de nombreux examens pour une situation qui aurait pu être évitée.

No benefits of #probiotics in #children with acute #diarrhea: results of 2 large RCT in US and Canada, freshly published in today edition of @NEJM.

New data to add to my talk on probiotics in pediatrics to be given this Friday 23rd November- @CHUSainte-Justine pediatric conference. https://lnkd.in/g_EUu_4

Cette année nous aurons un kiosque pendant cet événement.

Ça sera une belle célébration autour de la recherche.

Nous recherchons un étudiant au doctorat et un étudiant à la maîtrise pour travailler sur nos projets.

https://www.chusj.org/Calendrier-salle-presse/calendrier/Evenements/CDR/2018/Soiree-portes-ouvertes

Nous sommes heureux d’avoir reçu un financement pour la réalisation de notre projet de recherche par l’organisme Crohn et Colite Canada.

Cet essai clinique multicentrique randomisé en double aveugle pancanadien permettra de répondre à une question fondamentale sur les bénéfices des fortes doses de vitamine D chez les enfants et adolescents atteints de la maladie de Crohn.

L’étude ViDiPec inclura 316 patients avec maladie de Crohn en rémission qui seront aléatoirement répartis dans deux groupes de traitement : dose standard quotidienne de vitamine D3 ou une forte dose quotidienne de vitamine D3.

Le suivi sera de 52 semaines pour chaque patient.

Le critère de jugement principal sera le taux de rechutes de la maladie de Crohn entre les deux groupes.

D’autres critères de jugement tels la qualité de vie etc. seront également analysés.

Cet essai clinique est également soutenu par le réseau canadien des maladies inflammatoires pédiatriques (CIDSCANN)

https://recherche.chusj.org/fr/Communications/Nouvelles/2018-(1)/Crohn-et-Colite-Canada-octroie-2-7-millions-$-en-n

http://crohnsandcolitis.ca/News-Events/News-Releases/Crohn-s-and-Colitis-Canada-awards-$2-7-million-in

Heureux d’avoir obtenu ce financement  des Instituts de recherche en santé du Canada (IRSC) IRSC qui nous permettra en collaboration avec ma consœur Dr Marie-Claude Rousseau de INRS – Armand Frappier de mener notre projet concernant les facteurs de risques associés aux Maladies Inflammatoires Intestinales.

http://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=380766&lang=fr

Studying inflammatory bowel disease etiology: a life course approach

Inflammatory bowel disease is a chronic disease of the gut. It affects digestion and absorption of food, and elimination of waste. Its causes are unknown. After many studies, researchers have only been able to identify a few risk factors with certainty. They include family history of the disease and cigarette smoking.

The causes of this disease are still unknown, but some researchers think that certain times in life could be more critical for the development of the disease. Our goal is to clarify the causes of disease, and identify which ones could be targeted by prevention program.

We will study medical, lifestyle, and psychosocial factors from the time of birth until adult years. We will determine if they are linked to the development of the disease. These factors are for example prematurity, breastfeeding, antibiotic use, diet, smoking, stress. We will also study carefully when these factors occur during a person’s life.

For this research, we will use a cohort of about 400,000 persons born between 1970 and 1974, in the province of Quebec, Canada. We created this cohort for a previous study by linking together some provincial administrative databases. Data on medical services and hospitalizations for inflammatory bowel disease were obtained until 2014 and will be used to determine who is affected by the disease.

Then, we will ask about 2600 persons of the cohort to complete a web survey to obtain additional information. Among the participants, we will compare persons who have the disease to those who do not, and evaluate what are the key moments throughout their lives when these factors could increase the risk of the disease.

This research will help understanding which factors increase the risk of inflammatory bowel disease by detecting if there are certain times in a person’s life that are especially important. We will produce crucial information to establish prevention programs.

poster-advances-in-ibd-congress_fc

Live Demo : ICI

La cinquième édition du congrès mondial de gastro-entérologie pédiatrique aura lieu à Montréal  du 5 au 8  octobre 2016.

Plusieurs experts gastro-entérologue hépatologues et nutritionnistes pédiatres  du monde entier se donnent rendez-vous pour cet événement qui se tient tous les quatre dans divers continents. Il s’agit de la deuxième année où cela a lieu dans le continent américain.
Notre  laboratoire de recherche présentera plusieurs des travaux lors de ce congrès : Liste ci-dessous

Quality indicators in pediatric digestive endoscopy: lessons learned from a high volume endoscopy unit.

Anne-Sophie Groleau … Prévost Jantchou

Oral presentation

Endoscopy Imaging

Saturday, October 8, 2016.

16:00PM

Development and validation of a satisfaction questionnaire for pediatric digestive endoscopy .

Mélissandre Ostiguy …Prévost Jantchou

poster number 109

Friday, October 7, 2016

Usefulness of a pediatric infalmmatory bowel disease database for nurse follow-up of a big cohort.

poster number 19.

Friday, October 7, 2016 and Saturday, October 8, 2016.

France Gervais…Prévost Jantchou

Building a clinical and research database for children with inflammatory bowel disease (pedidata) : a step-by-step process.

Prévost Jantchou

Thursday, October 6, 2016.

poster number 252.

Phenotypic caracterization, indication and outcome of children with inflammatory bowel disease receiving blood transfusion.

Arafa Djalal…Prévost Jantchou

Friday, October 7, 2016

Outcome at 8 weeks of children treated with exclusive enteral nutrition (Modulen).

Amélie Roch…Prévost Jantchou

Poster number 229

Friday, October 7, 2016

Therapeutic drug monitoring is a new tool for improving the care of patients treated for Inflammatory bowel disease 

Mallory Chavannes… Prevost Jantchou

Thursday, October 6, 2016.

Poster number 235
Rejoignez nous pour cette belle fête scientifique. 

http://www.wcpghan2016.com/scientific-programme.html

Therapeutic Drug Monitoring is a new tool for improving the care of patients treated by antiTNFalpha: does this apply to children with Inflammatory Bowel Diseases?

1. Abstract
2. Poster: PDF
3. List of references :
   1.Kelsen J, Baldassano RN. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis. 2008;14 Suppl 2:S9-11. doi: 10.1002/ibd.20560. PubMed PMID: 18816756.
   2.Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541-9. doi: 10.1016/S0140-6736(02)08512-4. PubMed PMID: 12047962.
   3.Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. doi: 10.1056/NEJMoa050516. PubMed PMID: 16339095
   4.Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. PubMed PMID: 17324398.
   5.Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248-54. doi: 10.1016/j.cgh.2006.06.025. PubMed PMID: 16931170.
   6.Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19(12):2568-76. doi: 10.1097/MIB.0b013e3182a77b41. PubMed PMID: 24013361.
   7.Singh N, Rosenthal CJ, Melmed GY, Mirocha J, Farrior S, Callejas S, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(10):1708-13. doi: 10.1097/MIB.0000000000000137. PubMed PMID: 25153505.